Evidence map›Paper›PMID 34876159›Full record

ArticleVirology journal2021

Expression of plasma IFN signaling-related miRNAs during acute SARS-CoV-2 infection and its association with RBD-IgG antibody response.

Jing Wu, Xingxiang Liu, Jianguo Shao, Yuanyuan Zhang, Renfei Lu, Hong Xue, Yunfang Xu, Lijuan Wang, Hui Zhou, Lugang Yu and 2 more

Open access · goldAbstract read
In one paragraph

Article in Virology journal, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
0.8field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Cellular microRNAs target SARS-CoV-2 spike protein and restrict viral replication.American journal of physiology. Cell physiology · 2023
    Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 1 country.

Jing Wu *Department of Epidemiology and Statistics, School of Public Health, Medical College of Soochow University, Soochow, China.
Xingxiang Liu *Department of Clinical Laboratory, Huai'an Fourth People's Hospital, Huai'an, China.
Jianguo Shao *Nantong Third People's Hospital, Nantong, China.
Yuanyuan ZhangDepartment of Clinical Laboratory, Huai'an Fourth People's Hospital, Huai'an, China.
Renfei LuNantong Third People's Hospital, Nantong, China.
Hong XueNantong Third People's Hospital, Nantong, China.
Yunfang XuDepartment of Clinical Laboratory, Huai'an Fourth People's Hospital, Huai'an, China.
Lijuan WangDepartment of Clinical Laboratory, Huai'an Fourth People's Hospital, Huai'an, China.
Hui ZhouSuzhou Industrial Park Centers for Disease Control and Prevention, Soochow, China.
Lugang YuSuzhou Industrial Park Centers for Disease Control and Prevention, Soochow, China.
Ming YueDepartment of Infectious Diseases, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China. njym08@163.com.
Chen DongDepartment of Epidemiology and Statistics, School of Public Health, Medical College of Soochow University, Soochow, China. cdong@suda.edu.cn.
Huai'an City Fourth People's Hospital · CNSecond People's Hospital of NanTong · CNSoochow University · CNJiangsu Province Hospital · CNNantong University · CN

Funding

National Natural Science Foundation of China 81773507Special Foundation for COVID-19 from Nantong HS2020002Special Foundation for COVID-19 from Soochow University JJ13900420The Foundation of Technology Program in Soochow SYS2020049
6 · The paper itself

Abstract

backgroundCoronavirus disease 2019 (COVID-19) is a huge challenge worldwide. Although previous studies have suggested that type I interferon (IFN-I) could inhibit the virus replication, the expression characteristics of IFN-I signaling-related miRNAs (ISR-miRNAs) during acute severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection and its relationship with receptor-binding domain (RBD) IgG antibody response at the recovery phase remain unclear.

methodsExpression profiles of 12 plasma ISR-miRNAs in COVID-19 patients and healthy controls were analyzed using RT-qPCR. The level of RBD-IgG antibody was determined using the competitive ELISA. Spearman correlation was done to measure the associations of plasma ISR-miRNAs with clinical characteristics during acute SARS-CoV-2 infection and RBD-IgG antibody response at the recovery phase.

resultsCompared with the healthy controls, COVID-19 patients exhibited higher levels of miR-29b-3p (Z = 3.15, P = 0.002) and miR-1246 (Z = 4.98, P < 0.001). However, the expression of miR-186-5p and miR-15a-5p were significantly decreased. As the results shown, miR-30b-5p was negatively correlated with CD4 + T cell counts (r = - 0.41, P = 0.027) and marginally positively correlated with fasting plasma glucose in COVID-19 patients (r = 0.37, P = 0.052). The competitive ELISA analysis showed the plasma level of miR-497-5p at the acute phase was positively correlated with RBD-IgG antibody response (r = 0.48, P = 0.038).

conclusionsOur present results suggested that the expression level of ISR-miRNAs was not only associated with acute SARS-CoV-2 infection but also with RBD-IgG antibody response at the recovery phase of COVID-19. Future studies should be performed to explore the biological significance of ISR-miRNAs in SARS-CoV-2 infection.

Indexed as

MicroRNAsAntibodies, ViralCase-Control StudiesCOVID-19COVID-19 Nucleic Acid TestingEnzyme-Linked Immunosorbent AssayFemaleHumansImmunoglobulin GInterferon Type IMaleMiddle AgedSARS-CoV-2Virus ReplicationAntibodies, ViralImmunoglobulin GInterferon Type IMicroRNAsCOVID-19IFN-I signaling pathwayMicroRNARBD-IgGSARS-CoV-2

Identifiers

PMID34876159
PMCPMC8649682
OpenAlexW4200267745

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.